ERBB2 and breast cancer: With regard to HER2 status determination, clinical guidelines and stratification of BC into HER2-negative (neg), equivocal or HER2-pos cases are defined by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) [38].